Secondary Prevention of Noncardioembolic Ischemic Stroke This supplement to The American Journal of Managed Care provides information on the epidemiology, symptoms, risk factors, burden, and treatment options related to noncardioembolic ischemic stroke and transient ischemic attack, with particular focus on secondary prevention of recurrent stroke using antiplatelet agents.
It is the policy of The American Journal of Managed Care to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.
In accordance with the ACCME, participants for this activity have completed conflict-of-interest statements.
Jeffrey D. Dunn, PharmD, MBA
Faculty
SelectHealth
Marc Fisher, MD
Department of Neurology
University of Massachusetts Memorial Medical Center
Professor and Vice Chair
Vanderbilt Stroke Center
These participants report relationships with the following corporate organizations:
Consultant:
Consultant/Speakers’ bureau:
Investigator/Speakers’ bureau/Consultant:
Investigator/Speakers’ bureau:
GOA
L
This educational activity is intended for managed care professionals (medical directors and pharmacy directors plus other key personnel in HMOs, PPOs, IHOs, group practices, hospitals, nursing homes, home healthcare, the government [including the Centers for Medicare & Medicaid Services], and employer-based groups).
EDUCATIONAL OBJECTIVES
Release Date: June 30, 2008.
This publication was made possible by an educational grant from Boehringer Ingelheim.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.